Evidence map›Paper›PMID 39362028›Full record

ArticleBiochemical and biophysical research communications2024

Famotidine increases cellular phospho-tyrosine levels.

Imanol Zubiete-Franco, Nicholas K Tonks

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical and biophysical research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Imanol Zubiete-FrancoCold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11724, USA.
Nicholas K TonksCold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11724, USA. Electronic address: tonks@cshl.edu.

Funding

Single-Cell Biology Shared ResourceP30CA045508 · COLD SPRING HARBOR LABORATORY · 1987 to 2025
$27.2M
Protein Tyrosine Dephosphorylation &signal TransductionR37CA053840 · COLD SPRING HARBOR LABORATORY · 2001 to 2005
$3.2M
PROTEIN TYROSINE DEPHOSPHORYLATION &SIGNAL TRANSDUCTIONR01CA053840 · COLD SPRING HARBOR LABORATORY · 1991 to 2025
$1.3M
Receptor PTPs, Cell Contact and Signal TransductionR01DK124907 · NIDDK · COLD SPRING HARBOR LABORATORY · PI NICHOLAS K TONKS · 2022 to 2023
$960k
NCI NIH HHS P30 CA045508NCI NIH HHS R01 CA053840NCI NIH HHS R37 CA053840NIDDK NIH HHS R01 DK124907
6 · The paper itself

Abstract

While vaccines were being developed, the SARS-CoV-2 pandemic triggered a race to find known drugs that could be quickly repurposed to treat patients. One such candidate was famotidine, which retrospective cohort studies had shown increased survival in hospitalized patients. Computational studies had suggested that famotidine may target early viral proteases; however, ultimately, famotidine was shown not to function as a viral inhibitor. In contrast, we have observed a change in the cellular levels of phospho-tyrosine in A549 lung epithelial cells following treatment with famotidine. This quick change in phosphorylation was due mainly to a dose-dependent increase in cellular production of H

Indexed as

FamotidineA549 CellsAntiviral AgentsCOVID-19COVID-19 Drug TreatmentHumansHydrogen PeroxideInterferon-alphaPhosphorylationPhosphotyrosineSARS-CoV-2Signal TransductionTyrosineAntiviral AgentsFamotidineHydrogen PeroxideInterferon-alphaPhosphotyrosineTyrosineCovid-19FamotidineHistamine 2 receptorInterferon alphaReactive oxygen speciesTyrosine phosphorylation

Identifiers

PMID39362028
PMCPMC11490372

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.